# Larimar Therapeutics, Inc.: overview LRMR · Nasdaq · CIK 1374690 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lrmr.md) · [Financials](/companies/lrmr/financials.md) · [Filings](/companies/lrmr/filings.md) · [Insiders](/companies/lrmr/insiders.md) Latest reported revenue: [$0](/filings/0001564590-20-022942.md) for Q1 FY2020, three months to 2020-03-31, from the 10-Q filed May 7, 2020 (XBRL us-gaap:Revenues, accession 0001564590-20-022942). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.24)](/filings/0001193125-25-266969.md) | not reported | [(0.46)](/filings/0000950170-25-061222.md) | [(0.41)](/filings/0000950170-25-108797.md) | [(0.61)](/filings/0001193125-25-266969.md) | not reported | not reported | not reported | | Free cash flow | $m | [(24.6) d](/filings/0000950170-24-119100.md) | [(22.0) d](/filings/0001193125-26-115878.md) | [(26.6)](/filings/0001193125-26-224087.md) | [(19.4) d](/filings/0001193125-26-331529.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.95)](/filings/0000950170-23-007855.md) | [(1.37)](/filings/0000950170-24-031529.md) | [(0.84)](/filings/0000950170-25-043925.md) | [(1.32)](/filings/0000950170-25-043925.md) | not reported | | Free cash flow | $m | [(42.4)](/filings/0000950170-23-007855.md) | [(27.7)](/filings/0000950170-24-031529.md) | [(33.6)](/filings/0000950170-25-043925.md) | [(71.3)](/filings/0001193125-26-115878.md) | [(113)](/filings/0001193125-26-115878.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lrmr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $108.6m | 35,606,974 | | Unchanged | | [Blue Owl Capital Holdings LP](/funds/1858703.md) | 2026-06-30 | $27.9m | 9,163,157 | | Added +2,043,150 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $17.3m | 5,678,035 | | Added +1,925,835 | | [Defilade Capital Management, L.P.](/funds/2088557.md) | 2026-06-30 | $11.2m | 3,670,135 | | New +3,670,135 | | [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $9.6m | 3,163,423 | | Added +229,024 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.1m | 2,974,901 | | Added +108,552 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $7.8m | 2,565,999 | | Added +1,065,999 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $7.2m | 2,371,414 | | Added +1,553,897 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $6.1m | 2,012,458 | | Added +1,078,994 | | [DAFNA Capital Management LLC](/funds/1389933.md) | 2026-06-30 | $6.1m | 2,008,164 | | Reduced −21,000 | ## Recent filings [All 684 filings](/companies/lrmr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 20:06 ET | [8-K](/filings/0001193125-26-407331.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-407331 | | 2026-08-04 | 11:12 ET | [10-Q](/filings/0001193125-26-331529.md) | Quarterly report, period 2026-06-30 | 0001193125-26-331529 | | 2026-08-04 | 11:02 ET | [8-K](/filings/0001193125-26-331516.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-331516 | | 2026-06-29 | 10:33 ET | [8-K](/filings/0001193125-26-286780.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-286780 | | 2026-05-19 | 20:27 ET | [8-K](/filings/0001193125-26-230852.md) | 5.07 Shareholder vote results | 0001193125-26-230852 | | 2026-05-14 | 20:18 ET | [10-Q](/filings/0001193125-26-224087.md) | Quarterly report, period 2026-03-31 | 0001193125-26-224087 | | 2026-05-14 | 11:02 ET | [8-K](/filings/0001193125-26-222746.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-222746 | | 2026-04-20 | 20:06 ET | [DEF 14A](/filings/0001193125-26-163942.md) | Proxy statement, period 2026-04-17 | 0001193125-26-163942 | | 2026-03-19 | 19:41 ET | [10-K](/filings/0001193125-26-115878.md) | Annual report, period 2025-12-31 | 0001193125-26-115878 | | 2026-03-19 | 11:04 ET | [8-K](/filings/0001193125-26-115119.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-115119 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-115878.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1374690 - Tickers: LRMR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.